Srikala S. Sridhar

Apr 28, 2024 | cco.amegroups.org | Jenny Peng |Srikala S. Sridhar |Di Jiang

Have a website account?Log In orRegister for exclusive website content. Home / Vol 13, No 2 (April 30, 2024) / Triplet therapy for metastatic hormone sensitive prostate cancer—looking beyond volume of disease PDF 432 views Full Text 5 views Peer Review File 70 views COI Form 58 views

Nov 14, 2023 | bpno.dk | Srikala S. Sridhar

november 2023 This MEDtalk provides background information about muscle-invasive bladder cancer, the standard treatment approaches, and the challenges of cisplatin-ineligible patients. Dr. Srikala Sridhardescribes the study design and the results of Study EV-103 Cohort L, including the pathological complete response rate and safety profile of the treatment with enfortumab vedotin in the neoadjuvant setting.

Apr 20, 2023 | mdpi.com | Abhenil Mittal |Srikala S. Sridhar |Michael Ong |Di Jiang

Open AccessReviewbyAbhenil Mittal 1, Srikala S. Sridhar 1, Michael Ong 2 and Di Maria Jiang 1,* 1Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, Toronto, ON M5G 2C1, Canada2Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada*Author to whom correspondence should be addressed. Curr. Oncol.

Mar 7, 2023 | urotoday.com | Srikala S. Sridhar

Read the Full Video TranscriptPetros Grivas: Hello, I'm Dr. Petros Grivas. I'm a medical oncologist and associate professor at the University of Washington and Fred Hutchinson Cancer Center. I'm really excited I'm here today to host Dr. Kala Sridhar. Dr. Sridhar is a very well known medical oncologist internationally. She's a full professor at the University of Toronto, and she's the director of the GU Medical Oncology Program at the University of Toronto British Margaret Cancer Center there.

Feb 22, 2023 | onclive.com | Srikala S. Sridhar

Srikala Sridhar, MD, MSc, FRCPC, clinician investigator, Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer, discusses long-term follow-up data from the phase 3 JAVELIN Bladder 100 (NCT02603432) in patients with advanced urothelial carcinoma. The study compared first-line avelumab (Bavencio) maintenance therapy plus best supportive care vs best supportive care alone in patients with locally advanced or metastatic urothelial carcinoma.